|
π
|
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease
7 auth.
Daniel A. Ryskamp,
Jun Wu,
M. Geva,
R. Kusko,
I. Grossman,
Michael Hayden,
...
I. Bezprozvanny
|
6 |
2017 |
6
π
|
|
π
|
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
119 auth.
R. Reilmann,
A. McGarry,
I. Grachev,
J. Savola,
B. Borowsky,
E. Eyal,
Nicholas Gross,
D. Langbehn,
R. Schubert,
A. Wickenberg,
S. Papapetropoulos,
Michael Hayden,
F. Squitieri,
K. Kieburtz,
G. Landwehrmeyer,
...
P. Agarwal,
K. Anderson,
N. Aziz,
J. Azulay,
A. Bachoud-LΓ©vi,
R. Barker,
Agnieszka Bebak,
M. Beuth,
K. Biglan,
S. Blin,
S. Bohlen,
R. Bonelli,
Sue Caldwell,
F. Calvas,
Jonielyn Carlos,
Simona Castagliuolo,
Terrence Chong,
P. Chua,
A. Coleman,
J. Corey-Bloom,
R. Cousins,
D. Craufurd,
Jill Davison,
Γ. Decorte,
G. Michele,
Laura Dornhege,
A. Feigin,
Stephanie Gallehawk,
P. Gauteul,
Carey Gonzales,
J. Griffith,
A. Gustov,
M. Guttman,
Beat Heim,
Hope Heller,
L. Hjermind,
S. Illarioshkin,
L. Ivanko,
J. Jaynes,
M. Jenckes,
Barbara Kaminski,
Anna Kampstra,
Agnieszka Konkel,
S. Kopishinskaya,
P. Krystkowiak,
Suresh K Komati,
Alexander Kwako,
Stefan Lakoning,
G. Latipova,
B. Leavitt,
C. Loy,
C. MacFarlane,
Louise Madsen,
K. Marder,
S. Mason,
Neila Mendis,
T. Mendis,
A. NΓ©meth,
L. Nevitt,
V. Norris,
C. OβNeill,
Audrey Olivier,
M. Orth,
Ashley Owens,
P. Panegyres,
S. Perlman,
J. Preston,
J. Priller,
Alicja Puch,
O. Quarrell,
Domenica Ragosta,
A. Rialland,
H. Rickards,
A. Romoli,
Christopher Ross,
A. Rosser,
M. RudziΕska,
Cinzina V Russo,
C. Saft,
V. Segro,
K. Seppi,
Barbara Shannon,
D. Shprecher,
C. Simonin,
Z. Skitt,
J. SΕawek,
P. Soliveri,
S. Sorbi,
Valarie Suski,
I. StΔpniak,
Park Sungmee,
S. Temirbaeva,
C. Testa,
Anette Torvin-Moller,
Stefan Uhl,
Christina Vangsted-Hansen,
C. Verny,
P. Wall,
F. Walker,
Paula Wasserman,
G. Witkowski,
Jan Wright,
Z. Zalyalova,
D. Zielonka
|
6 |
2019 |
6
π
|
|
π
|
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor
8 auth.
Daniel A. Ryskamp,
Lili Wu,
Jun Wu,
Dabin Kim,
G. Rammes,
M. Geva,
...
Michael Hayden,
I. Bezprozvanny
|
5 |
2019 |
5
π
|
|
π
|
Laquinimod treatment in the R6/2 mouse model
11 auth.
G. Ellrichmann,
A. Blusch,
O. Fatoba,
Janine Brunner,
C. Reick,
L. Hayardeny,
...
Michael Hayden,
Dominik A. Sehr,
K. Winklhofer,
C. Saft,
R. Gold
|
5 |
2017 |
5
π
|
|
π¬
|
Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis
K. Pitarokoili,
B. Ambrosius,
L. Schrewe,
L. Hayardeny,
Michael Hayden,
R. Gold
|
3 |
2014 |
3
π¬
|
|
π
|
Author Correction: Laquinimod treatment in the R6/2 mouse model
11 auth.
G. Ellrichmann,
A. Blusch,
O. Fatoba,
Janine Brunner,
C. Reick,
L. Hayardeny,
...
Michael Hayden,
Dominik A. Sehr,
K. Winklhofer,
C. Saft,
Ralf Gold
|
1 |
2019 |
1
π
|
|
π’
|
Down's syndrome and Alzheimer's disease
O. Suchowersky,
Michael Hayden
|
0 |
1984 |
0
π’
|
|
π
|
O1-03-07 ABCA1 modulates APOE levels in brain and plasma
7 auth.
Veronica Hirsch-Reinshagen,
Steven Zhou,
Jeniffer Y. Chan,
Sean A. McIsaac,
J. Cohn,
Michael Hayden,
...
C. Wellington
|
0 |
2004 |
0
π
|
